Rare disease patient insight subscription platform launched
PatientSight is a subscription-based platform aimed at those working in life science market research, marketing, new product planning, consulting, communications, and other functions involved with rare disease areas.
The platform organises the patient journey by disease, treatment and brand experience, with surveys recurring throughout the year.
PatientSight is co-founded by healthcare industry veteran Dave Muggler, who has spent 20 years in life science market research and analytics and previously held roles at PDI, Syneos Health and TGaS Advisors.
Alongside Muggler, co-founder Jason Fox has held various positions in healthcare and pharmaceuticals, with a focus on data analytics and client service. He previously ran the syndicated market research business lines at Verispan, InVentiv and Syneos Health.
Dave Muggler, president, and co-founder of PatientSight, said: “The successful planning and marketing of new products and treatments for rare diseases requires a constant finger on the pulse of these unique patient types.”
PatientSight partners with patient recruitment company Rare Patient Voice, which has a network of around 145,000 patients covering 1,500 rare and non-rare diseases.
Wes Michael, president, Rare Patient Voice, said: “Together, we look forward to sharing the opinions and insights of patients with researchers and companies, so they can be considered in the development and management of new and current life-changing products and services.”

We hope you enjoyed this article.
Research Live is published by MRS.
The Market Research Society (MRS) exists to promote and protect the research sector, showcasing how research delivers impact for businesses and government.
Members of MRS enjoy many benefits including tailoured policy guidance, discounts on training and conferences, and access to member-only content.
For example, there's an archive of winning case studies from over a decade of MRS Awards.
Find out more about the benefits of joining MRS here.
0 Comments